540359 Stock Overview
Operates in the pharmaceutical business in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Parmax Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹43.70 |
| 52 Week High | ₹54.00 |
| 52 Week Low | ₹24.18 |
| Beta | 0 |
| 1 Month Change | -5.00% |
| 3 Month Change | -2.13% |
| 1 Year Change | 32.87% |
| 3 Year Change | -25.93% |
| 5 Year Change | 142.78% |
| Change since IPO | 249.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 540359 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.0% | 0.8% | -4.2% |
| 1Y | 32.9% | 39.7% | 19.1% |
Return vs Industry: 540359 underperformed the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: 540359 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| 540359 volatility | |
|---|---|
| 540359 Average Weekly Movement | 7.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 540359's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 540359's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | n/a | Umang Gosalia | www.parmaxpharma.com |
Parmax Pharma Limited operates in the pharmaceutical business in India. It manufactures and sells bulk drugs, drug intermediates, and specialty chemicals. The company was incorporated in 1994 and is based in Rajkot, India.
Parmax Pharma Limited Fundamentals Summary
| 540359 fundamental statistics | |
|---|---|
| Market cap | ₹163.49m |
| Earnings (TTM) | ₹0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs 540359 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 540359 income statement (TTM) | |
|---|---|
| Revenue | ₹0 |
| Cost of Revenue | ₹0 |
| Gross Profit | ₹0 |
| Other Expenses | ₹0 |
| Earnings | ₹0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 540359 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:30 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Parmax Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|